[SCHEDULE 13G/A] KESTRA MEDICAL TECHNOLOGIES, LTD. SEC Filing

Rhea-AI Filing Summary

FMR LLC and Abigail P. Johnson reported beneficial ownership of 5,225,988 shares of Kestra Medical Technologies Inc. common stock, representing 10.2% of the class as of the event date 09/30/2025. The filing shows FMR LLC holds 5,225,753 shares with sole voting power and 5,225,988 shares with sole dispositive power; Abigail P. Johnson is reported with sole dispositive power over the same 5,225,988 shares. The statement is filed on Schedule 13G (Amendment No. 1), indicating the position is held in the ordinary course of business and not for the purpose of changing or influencing control. Signatures indicate filings were executed on 10/06/2025 and reference powers of attorney attached to earlier Schedule 13G filings.

Positive

• Transparent disclosure of a material stake (10.2%) improves investor visibility
• Schedule 13G filing indicates the position is held in the ordinary course and not for control, reducing short‑term governance uncertainty

Negative

• Material ownership concentration at 10.2% could still influence outcomes if intentions change
• Exhibit 99 referenced but not included in the body here, leaving subsidiary/agreements details unclear

Insights

Institutional Ownership Analyst

Large passive stake disclosed: 10.2% held by FMR LLC/Abigail P. Johnson.

Holding 5,225,988 shares equal to 10.2% signals a material non‑control position under Schedule 13G treatment, which typically denotes passive intent rather than an active control campaign. The filing records sole dispositive power for both the firm and the named individual over the same share count, reflecting reporting rules for shared investment management structures.

Risks include potential future reclassification to Schedule 13D if intent changes; monitor any subsequent filings or public statements within the next months that would indicate active acquisition or control intentions.

Corporate Governance Specialist

Disclosure strengthens transparency on large shareholder composition.

The report clarifies that the position was "acquired and held in the ordinary course of business" and not for changing control, which is the threshold distinction between 13G and 13D filings. The inclusion of precise voting and dispositive power numbers helps investors assess potential influence: sole voting power is 5,225,753 and sole dispositive power is 5,225,988.

Watch for any related exhibits or subsequent amendments that identify subsidiaries or agreements (the filing references an Exhibit 99). If none appear within typical SEC amendment windows, governance impact is likely limited in the near term.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

KESTRA MEDICAL TECHNOLOGIES INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

G52441105

(CUSIP Number)

09/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. G52441105

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 5,225,753.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,225,988.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,225,988.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. G52441105

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 5,225,988.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,225,988.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

10.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: KESTRA MEDICAL TECHNOLOGIES INC
(b)	Address of issuer's principal executive offices: 3933 LAKE WASHINGTON BLVD NE,SUITE 200,KIRKLAND,WA,USA,98033
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: G52441105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 5225988.00
(b)	Percent of class: 10.2 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 5225988.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of KESTRA MEDICAL TECHNOLOGIES INC. No one other person's interest in the COMMON STOCK of KESTRA MEDICAL TECHNOLOGIES INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	10/06/2025

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	10/06/2025

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

What stake does FMR LLC report in Kestra Medical Technologies (KMTS)?

FMR LLC reports beneficial ownership of 5,225,988 shares, representing 10.2% of KMTS common stock.

Does Abigail P. Johnson have voting power over the shares reported?

The filing shows 0 shared voting power for Abigail P. Johnson and lists 5,225,988 shares under sole dispositive power; FMR LLC reports 5,225,753 shares with sole voting power.

Is this filing a Schedule 13G or 13D and what does that imply?

This is a Schedule 13G (Amendment No. 1), which typically indicates a passive investment held in the ordinary course, not intended to change or influence control.

When was the disclosure executed?

Signatures on the filing are dated 10/06/2025, with the event date listed as 09/30/2025.

Are there any subsidiaries or agreements disclosed related to the holding?

The filing references Exhibit 99 for a 13d-1(k)(1) agreement and incorporates earlier powers of attorney; the exhibit details are not included in the provided text.